Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Pancreatic Cancer.

Pancreatic cancer screening has advanced significantly in recent years. There are now research-based guidelines on screening ...

(Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced ...

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.

More information: Elias Saba et al, Oral bacteria accelerate pancreatic cancer development in mice, Gut (2024). DOI: 10.1136/gutjnl-2023-330941 Provided by Hebrew University of Jerusalem ...

SciSparc (SPRC)announced that MitoCareX Bio, its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into ...

(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...

Our optimized protocol dramatically increased the expression of NKX6.1, leading to an increase in the proportion of PDX1+/NKX6.1+ progenitors (~90%) and upregulation of the key TFs controlling ...